ARGX (argenx SE) Other Stockholders Equity : $1,047 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is argenx SE Other Stockholders Equity?

argenx SE's Other Stockholders Equity for the quarter that ended in Dec. 2024 was $1,047 Mil.

argenx SE's quarterly Other Stockholders Equity stayed the same from Jun. 2024 ($0 Mil) to Sep. 2024 ($0 Mil) but then increased from Sep. 2024 ($0 Mil) to Dec. 2024 ($1,047 Mil).

argenx SE's annual Other Stockholders Equity increased from Dec. 2022 ($535 Mil) to Dec. 2023 ($772 Mil) and increased from Dec. 2023 ($772 Mil) to Dec. 2024 ($1,047 Mil).

argenx SE Other Stockholders Equity Historical Data

The historical data trend for argenx SE's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Other Stockholders Equity Chart

argenx SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Stockholders Equity

Get a 7-Day Free Trial

373.02

535.25

771.73

1,047.23

argenx SE Quarterly Data
	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Stockholders Equity	Get a 7-Day Free Trial															771.73	-	-	-	1,047.23

argenx SE Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

argenx SE Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of argenx SE's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ARGNF:USA ARGXb:UK 0QW0:UK 1AEA:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.